WO2024101962A1 - Cellules génétiquement modifiées et leur utilisation - Google Patents
Cellules génétiquement modifiées et leur utilisation Download PDFInfo
- Publication number
- WO2024101962A1 WO2024101962A1 PCT/KR2023/018102 KR2023018102W WO2024101962A1 WO 2024101962 A1 WO2024101962 A1 WO 2024101962A1 KR 2023018102 W KR2023018102 W KR 2023018102W WO 2024101962 A1 WO2024101962 A1 WO 2024101962A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- present
- cell
- amino acid
- acid sequence
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 111
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims abstract description 98
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims abstract description 98
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims abstract description 96
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 86
- 108090000015 Mesothelin Proteins 0.000 claims abstract description 76
- 102000003735 Mesothelin Human genes 0.000 claims abstract description 75
- 230000019491 signal transduction Effects 0.000 claims abstract description 52
- 239000012634 fragment Substances 0.000 claims abstract description 47
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 29
- 230000008685 targeting Effects 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 173
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 84
- 108090000623 proteins and genes Proteins 0.000 claims description 81
- 239000013598 vector Substances 0.000 claims description 66
- 230000011664 signaling Effects 0.000 claims description 60
- 230000027455 binding Effects 0.000 claims description 51
- 108091033319 polynucleotide Proteins 0.000 claims description 44
- 102000040430 polynucleotide Human genes 0.000 claims description 44
- 239000002157 polynucleotide Substances 0.000 claims description 44
- 206010028980 Neoplasm Diseases 0.000 claims description 43
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 38
- -1 CD86 Proteins 0.000 claims description 35
- 201000011510 cancer Diseases 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 32
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 27
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 27
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 24
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 19
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 14
- 239000012642 immune effector Substances 0.000 claims description 14
- 229940121354 immunomodulator Drugs 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims description 12
- 102100022339 Integrin alpha-L Human genes 0.000 claims description 11
- 108091008874 T cell receptors Proteins 0.000 claims description 11
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 11
- 239000003446 ligand Substances 0.000 claims description 10
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims description 9
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 9
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims description 9
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 9
- 102100032818 Integrin alpha-4 Human genes 0.000 claims description 9
- 102100032816 Integrin alpha-6 Human genes 0.000 claims description 9
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 9
- 102100029197 SLAM family member 6 Human genes 0.000 claims description 9
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims description 9
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 9
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 210000004698 lymphocyte Anatomy 0.000 claims description 9
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 8
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 8
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 8
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 6
- 102100024263 CD160 antigen Human genes 0.000 claims description 6
- 102100038077 CD226 antigen Human genes 0.000 claims description 6
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 6
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 6
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims description 6
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 claims description 6
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims description 6
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 claims description 6
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims description 6
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 6
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims description 6
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 claims description 6
- 102100025323 Integrin alpha-1 Human genes 0.000 claims description 6
- 102100039904 Integrin alpha-D Human genes 0.000 claims description 6
- 102100022341 Integrin alpha-E Human genes 0.000 claims description 6
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 6
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 6
- 102100025304 Integrin beta-1 Human genes 0.000 claims description 6
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 6
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 6
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims description 6
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims description 6
- 102000014128 RANK Ligand Human genes 0.000 claims description 6
- 108010025832 RANK Ligand Proteins 0.000 claims description 6
- 102100027744 Semaphorin-4D Human genes 0.000 claims description 6
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 5
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 5
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 5
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 5
- 102100037904 CD9 antigen Human genes 0.000 claims description 4
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 4
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 4
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 4
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 4
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 4
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 4
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 3
- 108010056102 CD100 antigen Proteins 0.000 claims description 3
- 108010017009 CD11b Antigen Proteins 0.000 claims description 3
- 102100027207 CD27 antigen Human genes 0.000 claims description 3
- 101150013553 CD40 gene Proteins 0.000 claims description 3
- 108010062802 CD66 antigens Proteins 0.000 claims description 3
- 102100027217 CD82 antigen Human genes 0.000 claims description 3
- 101710139831 CD82 antigen Proteins 0.000 claims description 3
- 102100035793 CD83 antigen Human genes 0.000 claims description 3
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims description 3
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 claims description 3
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 3
- 101000585551 Equus caballus Pregnancy-associated glycoprotein Proteins 0.000 claims description 3
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 claims description 3
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 3
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 3
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 claims description 3
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 claims description 3
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 3
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 claims description 3
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 claims description 3
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 3
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims description 3
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 claims description 3
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 3
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 3
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims description 3
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 claims description 3
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 claims description 3
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 claims description 3
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims description 3
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims description 3
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 3
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 3
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 3
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims description 3
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims description 3
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims description 3
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims description 3
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 3
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 claims description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 3
- 108010041100 Integrin alpha6 Proteins 0.000 claims description 3
- 108010030465 Integrin alpha6beta1 Proteins 0.000 claims description 3
- 102100033016 Integrin beta-7 Human genes 0.000 claims description 3
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims description 3
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 claims description 3
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 claims description 3
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 3
- 101100236305 Mus musculus Ly9 gene Proteins 0.000 claims description 3
- 108091008877 NK cell receptors Proteins 0.000 claims description 3
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 3
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 3
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 3
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims description 3
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims description 3
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims description 3
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims description 3
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 claims description 3
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims description 3
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 claims description 3
- 102100029216 SLAM family member 5 Human genes 0.000 claims description 3
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 3
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 claims description 3
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 3
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 3
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims description 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 3
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims description 3
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 3
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 3
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 3
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 3
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims description 3
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 claims description 3
- 102000003675 cytokine receptors Human genes 0.000 claims description 3
- 108010057085 cytokine receptors Proteins 0.000 claims description 3
- 102000006495 integrins Human genes 0.000 claims description 3
- 108010044426 integrins Proteins 0.000 claims description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 102100038078 CD276 antigen Human genes 0.000 claims description 2
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 claims description 2
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 2
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 claims description 2
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 2
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims description 2
- 108091054437 MHC class I family Proteins 0.000 claims description 2
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims description 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 2
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 2
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 description 48
- 235000001014 amino acid Nutrition 0.000 description 36
- 239000002773 nucleotide Substances 0.000 description 36
- 125000003729 nucleotide group Chemical group 0.000 description 36
- 150000001413 amino acids Chemical class 0.000 description 34
- 108060001084 Luciferase Proteins 0.000 description 30
- 239000005089 Luciferase Substances 0.000 description 30
- 239000003550 marker Substances 0.000 description 29
- 239000000427 antigen Substances 0.000 description 28
- 108091007433 antigens Proteins 0.000 description 28
- 102000036639 antigens Human genes 0.000 description 28
- 230000014509 gene expression Effects 0.000 description 25
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 23
- 230000004068 intracellular signaling Effects 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 22
- 230000000694 effects Effects 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 229920001184 polypeptide Polymers 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 108060003951 Immunoglobulin Proteins 0.000 description 13
- 108700008625 Reporter Genes Proteins 0.000 description 13
- 239000002585 base Substances 0.000 description 13
- 102000018358 immunoglobulin Human genes 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 12
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 12
- 239000005090 green fluorescent protein Substances 0.000 description 12
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 11
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 11
- 201000002528 pancreatic cancer Diseases 0.000 description 11
- 208000008443 pancreatic carcinoma Diseases 0.000 description 11
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 208000005718 Stomach Neoplasms Diseases 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000012636 effector Substances 0.000 description 9
- 206010017758 gastric cancer Diseases 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 201000011549 stomach cancer Diseases 0.000 description 9
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 8
- 238000009169 immunotherapy Methods 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 238000010361 transduction Methods 0.000 description 8
- 230000026683 transduction Effects 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 7
- 108091005735 TGF-beta receptors Proteins 0.000 description 7
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 7
- 208000029742 colonic neoplasm Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 241000713880 Spleen focus-forming virus Species 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 230000002998 immunogenetic effect Effects 0.000 description 6
- 201000007270 liver cancer Diseases 0.000 description 6
- 208000014018 liver neoplasm Diseases 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 241000713666 Lentivirus Species 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 5
- 241000714474 Rous sarcoma virus Species 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 108010054624 red fluorescent protein Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108091005941 EBFP Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 2
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102100037935 Polyubiquitin-C Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 2
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 2
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 2
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 2
- 108010056354 Ubiquitin C Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 108010082025 cyan fluorescent protein Proteins 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 210000005033 mesothelial cell Anatomy 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 108010079892 phosphoglycerol kinase Proteins 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- PBTPTBMYJPCXRQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;hexadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCC(O)=O PBTPTBMYJPCXRQ-MGMRMFRLSA-N 0.000 description 1
- CSTRPYAGFNTOEQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O CSTRPYAGFNTOEQ-MGMRMFRLSA-N 0.000 description 1
- DYIOSHGVFJTOAR-JGWLITMVSA-N (2r,3r,4s,5r)-6-sulfanylhexane-1,2,3,4,5-pentol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CS DYIOSHGVFJTOAR-JGWLITMVSA-N 0.000 description 1
- REYLLNRLWCBKCM-YFKPBYRVSA-N (2s)-2-acetamido-4-sulfanylbutanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CCS REYLLNRLWCBKCM-YFKPBYRVSA-N 0.000 description 1
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- PVFFUHAAOKXVTK-UHFFFAOYSA-N 2-(methylamino)-4-oxopentanoic acid Chemical compound CNC(C(O)=O)CC(C)=O PVFFUHAAOKXVTK-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- 101710134681 40 kDa protein Proteins 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241001050985 Disco Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102300064574 Epidermal growth factor receptor isoform 2 Human genes 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 101000780443 Homo sapiens Alcohol dehydrogenase 1A Proteins 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 1
- 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 description 1
- 101600123877 Homo sapiens Epidermal growth factor receptor (isoform 2) Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 101150069255 KLRC1 gene Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 1
- 241001372913 Maraba virus Species 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 description 1
- 101100341510 Mus musculus Itgal gene Proteins 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102000027581 NK cell receptors Human genes 0.000 description 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000713810 Rat sarcoma virus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 102220492414 Ribulose-phosphate 3-epimerase_H35A_mutation Human genes 0.000 description 1
- 101100010928 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) tuf gene Proteins 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 101150001810 TEAD1 gene Proteins 0.000 description 1
- 101150074253 TEF1 gene Proteins 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 102100029898 Transcriptional enhancer factor TEF-1 Human genes 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 241000221013 Viscum album Species 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- LNHWXBUNXOXMRL-VWLOTQADSA-N belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 description 1
- 229950011276 belotecan Drugs 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 230000008622 extracellular signaling Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N gallic acid propyl ester Natural products CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 102000009543 guanyl-nucleotide exchange factor activity proteins Human genes 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- WDVGLADRSBQDDY-UHFFFAOYSA-N holmium(3+);trinitrate Chemical compound [Ho+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O WDVGLADRSBQDDY-UHFFFAOYSA-N 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000029316 human TGF-beta1 type III receptor (730-743) Human genes 0.000 description 1
- 108091022242 human TGF-beta1 type III receptor (730-743) Proteins 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940025708 injectable product Drugs 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229950001845 lestaurtinib Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical group FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229950008835 neratinib Drugs 0.000 description 1
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- 201000004228 ovarian endometrial cancer Diseases 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical class [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 108091005946 superfolder green fluorescent proteins Proteins 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- YODZTKMDCQEPHD-UHFFFAOYSA-N thiodiglycol Chemical compound OCCSCCO YODZTKMDCQEPHD-UHFFFAOYSA-N 0.000 description 1
- 229950006389 thiodiglycol Drugs 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
Definitions
- the present invention relates to genetically engineered immune effector cells and uses thereof to increase the therapeutic effect for diseases such as cancer by immunotherapy.
- Cellular immunotherapy is a very promising treatment method for cancer treatment.
- most immunotherapeutic approaches have the following limitations in their therapeutic effectiveness against most malignant tumors, including solid tumors: (1) Reduced expression of tumor antigens on the surface of tumor cells (which reduces detection of antigens by the immune system) Sikkim); (2) expression of ligands for inhibitory receptors such as PD1, NKG2A, and TIGIT; (3) upregulation of cellular checkpoints, such as CISH, leading to immune cell deactivation; and (4) induction of a microscopic environment that releases substances such as transforming growth factor- ⁇ (TGF- ⁇ ) and adenosine, which suppress immune responses and promote tumor cell proliferation and survival. Therefore, there is a need for an improved method of cellular immunotherapy that can solve at least one of the above-mentioned challenges.
- TGF- ⁇ transforming growth factor- ⁇
- TGF- ⁇ signaling plays an important role in cancer progression.
- Most cancer cells inactivate epithelial antiproliferative responses and benefit from increased TGF- ⁇ expression and autocrine TGF- ⁇ signaling through effects on gene expression, release of immunosuppressive cytokines, and epithelial plasticity.
- TGF- ⁇ plays a role in increasing invasion and metastasis of cancer cells, stem cell properties, and drug resistance.
- TGF- ⁇ released from cancer cells, stromal fibroblasts and other cells in the tumor microenvironment further promotes cancer progression by shaping the structure of the tumor and suppressing the anti-tumor activity of immune cells, thus creating an immunosuppressive environment and anti-cancer. Prevents or attenuates the effectiveness of immunotherapy. Therefore, inhibition of TGF- ⁇ signaling is considered a prerequisite and key means to improve the efficacy of current and future immunotherapies, including for tumors containing cancer cells that are unresponsive to TGF- ⁇ .
- MSLN Mesothelin
- MSLN-targeted immunotherapies reported to date support a favorable safety profile.
- MSLN includes at least oesophageal cancer, breast cancer, gastric cancer, cholangiocarcinoma, pancreatic cancer, colon cancer, lung cancer, and thymic carcinoma.
- CAR targets in many common solid tumors, such as mesothelioma, ovarian cancer, and endometrial cancer [Morello, A. et al. (2016) Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. Cancer Disco. 6(2); 133-46].
- One object of the present invention is to provide a peptide that can inhibit the transforming growth factor- ⁇ (TGF- ⁇ ) signaling pathway along with a chimeric antigen receptor (CAR) targeting mesothelin.
- the aim is to provide cells that have been genetically engineered to express.
- Another object of the present invention relates to a cell therapeutic agent comprising the genetically engineered cells.
- Another object of the present invention relates to pharmaceutical compositions for various uses containing the genetically engineered cells.
- a chimeric antigen receptor (CAR) targeting mesothelin MSLN
- cells genetically engineered to express a peptide or fragment thereof capable of inhibiting the transforming growth factor- ⁇ (TGF- ⁇ ) signaling pathway a chimeric antigen receptor (CAR) targeting mesothelin (MSLN)
- TGF- ⁇ transforming growth factor- ⁇
- “recombinant” or “manipulated” in relation to a peptide means having an amino acid sequence that has been altered as a result of the application of genetic engineering techniques to the nucleic acid encoding the peptide and to the cell or organism expressing the peptide.
- the terms “recombinant” or “engineered” mean having a nucleic acid sequence that has been altered as a result of the application of genetic engineering techniques. Genetic engineering technologies include PCR and DNA cloning technologies; Transfection, transduction, transformation and other gene transfer techniques; homologous recombination; site-specific mutation; and gene fusions.
- the term “genetically engineered” or “genetically engineered” refers to a cell or organism, or an ancestor thereof, whose genomic DNA sequence has been intentionally modified by recombinant technology.
- the “genetic manipulation” includes “gene transplantation.”
- methods for genetically manipulating the expression of the peptide or its fragment in the cell include biological methods such as vectors, specific receptors, or cell fusion methods, microinjection methods, electroporation methods, gene guns, or ultrasonic genes.
- biological methods such as vectors, specific receptors, or cell fusion methods, microinjection methods, electroporation methods, gene guns, or ultrasonic genes.
- a method of introducing the gene encoding the peptide or its fragment through a physical method such as the introduction method, or a chemical method such as the calcium phosphate coprecipitation method, liposome method, lipofection method, DEAE dextran method, or alkali metal method. can do.
- the chimeric antigen receptor; and peptides or fragments thereof; Foreign genes encoding the proteins can be introduced into the cells by transfecting the immune effector cells with vectors containing genes encoding each.
- the “chimeric antigen receptor (CAR)” is defined as a cell-surface receptor comprising an extracellular target-binding domain, a transmembrane domain, and an intracellular signaling domain, all of which are formed on a single protein. They exist together in combinations that are not found naturally. This particularly includes receptors in which the extracellular and intracellular signaling domains are not naturally found together on a single receptor protein.
- Mesothelin is a protein also called MSLN, and is a 40 kDa protein secreted by mesothelial cells.
- the protein was first identified by reaction with the monoclonal antibody K1, and through continued research, the mesothelin gene was linked to a glycophosphatidylinositol linkage and a 31-kDa shed fragment, megakaryocyte-potentiating factor (MPF). ) is known to encode a precursor protein that is processed to produce mesothelin, which is attached to the cell membrane. It has been suggested that mesothelin may be involved in cell adhesion, etc., but its biological function has not yet been clearly identified.
- the mesothelin may be composed of the amino acid sequence represented by SEQ ID NO: 1, but is not limited thereto.
- the chimeric antigen receptor includes a mesothelin binding domain, and may further include one or more selected from the group consisting of a hinge domain, a signal peptide domain, a transmembrane domain, and one or more signaling domains. .
- the chimeric antigen receptor of the present invention includes a mesothelin (MSLN) binding domain.
- MSLN mesothelin
- the mesothelin (MSLN) binding domain provided in the present invention can bind to mesothelin with higher affinity than the conventionally known anti-MSLN binding domain.
- the binding domain may be an antibody or a fragment thereof.
- the “antibody” refers to an immunoglobulin molecule that specifically binds to an antigen.
- the antibody may be a natural or recombinant intact immunoglobulin, or may be an immune-reactive portion of an intact immunoglobulin.
- Antibodies are generally tetramers of immunoglobulin molecules.
- the antibody is a tetrameric glycosylated protein composed of two light (L) chains of about 25 kDa each and two heavy (H) chains of about 50 kDa each. Two types of light chains, referred to as lambda and kappa, can be found in antibodies.
- immunoglobulins can be classified into five main classes A, D, E, G and M, several of which are subclasses (isotypes), such as IgG1, IgG2 , can be further subdivided into IgG3, IgG4, IgA1 and IgA2.
- Each light chain typically contains an N-terminal variable (V) domain (VL) and constant (C) domain (CL).
- Each heavy chain typically contains an N-terminal V domain (VH), three or four C domains (CH1-3), and a hinge region. The CH domain located closest to VH is named CH1.
- the VH and VL domains are composed of four regions of relatively conserved sequences, referred to as framework regions, which form the scaffold for three regions of hypervariable sequences (complementarity determining regions, CDRs) (FR1). , FR2, FR3 and FR4).
- CDRs contain most of the residues responsible for the specific interaction of the antibody with the antigen.
- the CDRs are referred to as CDR1, CDR2 and CDR3. That is, the CDR elements on the heavy chain are referred to as CDRH1, CDRH2, and CDRH3, while the CDR elements on the light chain are referred to as CDRL1, CDRL2, and CDRL3.
- CDRs are typically described in Sequences of Proteins of Immunological Interest, US Department of Health and Human Services (1991), eds. See Kabat CDR, as described in Kabat et al.
- Another standard for specifying the antigen binding site is by reference to the hypervariable loop described by Chothia. For example, Chothia, D. et al. (1992) J. Mol. Biol. 227:799-817; and Tomlinson et al. (1995) EMBO J. 14:4628-4638.
- Another standard is the AbM definition used in Oxford Molecular's AbM antibody modeling software. In general, for example, Protein Sequence and Structure Analysis of Antibody Variable Domains.
- the antibody may exist in various forms, including but not limited to polyclonal antibodies, monoclonal antibodies, Fv, Fab, F(ab)2, etc., and single chain antibodies and humanized antibodies (document.
- antibodies against the antigen can be obtained from immunized transgenic mice using conventional hybridoma techniques.
- Human immunoglobulin transgenes carried by transgenic mice rearrange during B cell differentiation and subsequently undergo class switching and somatic mutation. Accordingly, using this technique, it is possible to prepare therapeutically useful IgG, IgA, IgM and IgE antibodies, such as, but not limited to, IgGl (gamma 1) and IgG3. Details of these techniques for preparing human antibodies and human monoclonal antibodies and the protocols for preparing such antibodies can be found, for example, in PCT Publication Nos.
- “Humanized” antibodies retain similar antigenic specificity as the original antibody, i.e., the ability to bind, for example, MSLN in the present invention.
- the “antibody fragment” or “antigen-binding fragment” is shorter than the full-length antibody, but includes at least a partial variable region (e.g., one or more CDRs and/or one or more antigen-binding sites) that binds to the antigen of the antibody. Therefore, it refers to any portion of a full-length antibody that retains the binding specificity and at least partial specific binding ability of the full-length antibody. Accordingly, antigen-binding fragment refers to an antibody fragment that contains an antigen-binding portion that binds the same antigen as the antibody from which the antibody fragment was derived.
- Antibody fragments include antibody derivatives produced by enzymatic treatment of a full-length antibody, and derivatives produced synthetically, such as those produced recombinantly. Antibodies include antibody fragments. Antibody fragments include, but are not limited to, single chain Fv (scFv), Fab, Fab', F(ab')2, Fv, dsFv, double-antibody, Fd and Fd' fragments, and other fragments, including modified fragments. It is not limited (see, e.g., Methods in Molecular Biology, Vol 207: Recombinant Antibodies for Cancer Therapy Methods and Protocols (2003); Chapter 1; p3-25, Kipriyanov).
- Fragments may comprise multiple chains linked together, for example, through disulfide bonds and/or through peptide linkers.
- Antibody fragments generally contain at least or about 50 amino acids, and typically contain at least or about 200 amino acids.
- the antigen-binding fragment is an antibody (e.g., through replacement of a corresponding region) to obtain an antibody that immunospecifically binds to the antigen (i.e., exhibits a Ka of at least or at least about 107-108 M-1).
- a “functional fragment” or “anti-MSLN antibody analog” is a fragment or analog that can prevent or substantially reduce the ability of a receptor to bind a ligand or initiate signal transduction.
- functional fragment generally has the same meaning as "antibody fragment” and, in the case of an antibody, is a fragment capable of preventing or substantially reducing the ability of a receptor to bind a ligand or initiate signal transduction, such as Fv. , Fab, and F(ab')2.
- the “Fv” fragment consists of a dimer (VH-VL dimer) formed by the variable domains of one heavy chain and the variable domains of one light chain by non-covalent association.
- VH-VL dimer dimer
- the three CDRs of each variable domain interact to determine the target-binding site on the surface of the VH-VL dimer identical to the intact antibody.
- the six CDRs together confer the target-binding specificity of the intact antibody.
- a single variable domain or half of an Fv containing only three target-specific CDRs
- the “single chain Fv (scFv)” is a single chain antibody fragment having the variable regions of the heavy and light chains of the antibody linked together.
- scFv single chain Fv
- the scFv is desirable because it can be genetically engineered to be expressed as part of a single chain together with other components that make up the chimeric antigen receptor.
- the antigen binding domain is typically included as part of the extracellular portion of the chimeric antigen receptor and is capable of recognizing and binding the targeted antigen, here specifically mesothelin (MSLN).
- the scFv can be prepared according to methods known in the art (e.g., Bird et al., (1988) Science 242:423-426 and Huston et al., (1988) Proc. Natl. Acad Sci USA 85:5879-5883).
- ScFv molecules can be made by connecting the VH and VL regions using a flexible polypeptide linker.
- the scFv molecule includes a linker with optimized length and/or amino acid composition (e.g., Ser-Gly linker). Linker length can greatly affect how the variable region of the scFv folds and interacts. In fact, if short polypeptide linkers (e.g. 5-10 amino acids) are used, intrachain folding is prevented.
- interchain folding is required to bring the two variable regions into proximity to form a functional epitope binding site.
- linker orientation and size see, e.g., Hollinger et al. 1993 Proc Natl Acad. Sci. U.S.A. 90:6444-6448, U.S. Patent Application Publication Nos. 2005/0100543, 2005/0175606, 2007/0014794, and PCT Publication Nos. WO2006/020258 and WO2007/024715, the entire contents of each of which are incorporated herein by reference. Included.
- the mesothelin (MSLN) binding domain may include an scFv capable of specifically recognizing mesothelin.
- the mesothelin (MSLN) binding domain includes a light chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 2; Light chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 3; and a light chain variable region including a light chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 4.
- the mesothelin (MSLN) binding domain includes a heavy chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 5; Heavy chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 6; and a heavy chain variable region including a heavy chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 7.
- variable region In the present invention, the "variable region”, “variable domain”, “V region” or “V domain” is generally located at the amino-terminus of the light or heavy chain, about 120 to 130 amino acids in the heavy chain and about 100 amino acids in the light chain. Refers to the portion of the light or heavy chain of an antibody, ranging in length from 1 to 110 amino acids, and is used in the binding and specificity of each specific antibody for a specific antigen.
- the variable region of the heavy chain may be referred to as “VH”.
- VL variable region of the light chain
- the term “variable” refers to the fact that certain segments of the variable region vary widely in sequence among antibodies. The V region mediates antigen binding and defines the specificity of a particular antibody for a particular antigen.
- variable region is a frame of about 15 to 30 amino acids separated by shorter regions of greater variability (e.g., extreme variability), referred to as “hypervariable regions,” which are each about 9 to 12 amino acids long. It consists of a less variable (i.e. relatively invariant) stretch called the work region (FR).
- the variable regions of the heavy and light chains are composed of four FRs that predominantly adopt the ⁇ -sheet configuration, each connected by three hypervariable regions that form loops connecting, and in some cases form part of, the ⁇ -sheet structure. Includes.
- the hypervariable regions within each chain are closely held by FRs, and hypervariable regions from other chains contribute to the formation of the antigen-binding site of the antibody (see, e.g., Kabat et al., Sequences of Proteins of Immunological Interest (5th ed. 1991)].
- the constant region is not directly involved in the binding of the antibody to the antigen, but exhibits various effector functions, such as the antibody's participation in antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
- ADCC antibody-dependent cellular cytotoxicity
- CDC complement-dependent cytotoxicity
- Variable regions vary widely in sequence between different antibodies.
- the variable region is a human variable region.
- the "heavy chain” refers to a polypeptide chain of about 50 to 70 kDa, wherein the amino-terminal portion comprises a variable region of at least about 120 to 130 amino acids, and the carboxy-terminal portion comprises a constant region.
- Constant regions are of five distinct types, referred to as alpha ( ⁇ ), delta ( ⁇ ), epsilon ( ⁇ ), gamma ( ⁇ ), and mu ( ⁇ ), based on the amino acid sequence of the heavy chain constant region, isotype).
- the distinct heavy chains differ in size: ⁇ , ⁇ , and ⁇ contain approximately 450 amino acids, while ⁇ and ⁇ contain approximately 550 amino acids.
- IgA immunoglobulin A
- IgD immunoglobulin D
- IgE immunoglobulin G
- IgM immunoglobulin M
- Subclasses include IgG1, IgG2, IgG3 and IgG4.
- the “light chain” refers to a polypeptide chain of about 25 kDa, wherein the amino-terminal portion includes a variable region of about 100 to about 110 or more amino acids, and the carboxy-terminal portion includes a constant region.
- the approximate length of the light chain is 211 to 217 amino acids. Based on the amino acid sequence of the constant domain, there are two distinct types, referred to as kappa ( ⁇ ) or lambda ( ⁇ ).
- CDR is used interchangeably with “hypervariable region,” “HVR,” and “complementarity determining region.”
- CDR refers to one of the three hypervariable regions (H1, H2, or H3) within the non-framework region of an immunoglobulin (Ig or antibody) VH ⁇ -sheet framework or a non-framework region of the antibody VL ⁇ -sheet framework Refers to one of three hypervariable regions (L1, L2, or L3) within the hypervariable region.
- CDR1, CDR2 and CDR3 within the VH domain are also referred to as HCDR1, HCDR2 and HCDR3, respectively.
- CDR1, CDR2 and CDR3 within the VL domain are also referred to as LCDR1, LCDR2 and LCDR3, respectively. Accordingly, CDRs are variable region sequences interspersed within framework region sequences.
- CDR regions are well known to those skilled in the art and have been defined by a well-known numbering system.
- Kabat complementarity determining regions are based on sequence variability and are the most commonly used (e.g., Kabat et al., supra; Nick Deschacht et al., J Immunol 2010; 184 :5696-5704]).
- Chothia instead refers to the position of a structural loop (see, e.g., Chothia and Lesk, J. Mol. Biol. 196:901-17 (1987)).
- the end of the Chotia CDR-H1 loop varies between H32 and H34 depending on the length of the loop (this is because the Kabat numbering system places insertions at H35A and H35B; 35A or If neither 35B is present, the loop ends at 32; if only 35A is present, the loop ends at 33; if both 35A and 35B are present, the loop ends at 34.
- the AbM hypervariable region represents a compromise between the Kabat CDRs and Chotia structural loops and is used by Oxford Molecular's AbM antibody modeling software. “Contact” hypervariable regions are based on analysis of available complex crystal structures.
- IMGT ImMunoGeneTics
- IMGT ImMunoGeneTics
- IGs immunoglobulins
- TCRs T-cell receptors
- MHC major histocompatibility complexes
- CDRs are referred to both in terms of amino acid sequence and position within the light or heavy chain. Because the "position" of the CDRs within the structure of immunoglobulin variable domains is conserved between species and exist in structures referred to as loops, a numbering system is used to align variable domain sequences according to structural features, CDRs and framework residues. is easily identified.
- This information can be used to graft and replace CDR residues from one species of immunoglobulin into a recipient framework, typically from a human antibody.
- An additional numbering system (AHon) is described in Honegger and Plckthun, J. Mol. Biol. 309: 657-70 (2001)].
- the correspondence between numbering systems including, for example, the Kabat numbering and the IMGT unique numbering system, is well known to those skilled in the art.
- CDR complementarity determining region
- a scheme is specified for the identification of a specific CDR or CDRs, such as CDRs defined by the IMGT, Kabat, Chotia or Contact methods.
- the specific amino acid sequence of the CDR is provided.
- the CDR region can also be defined by a combination of various numbering systems, for example a combination of the Kabat and Chotia numbering systems or a combination of the Kabat and IMGT numbering systems. Accordingly, terms such as “CDR1 as presented in a particular VH” include, but are not limited to, any CDR1 as defined by the exemplary CDR numbering system described above. Once a variable region (e.g., VH or VL) is given, one skilled in the art will understand that the CDRs within the region may be defined by different numbering systems or combinations thereof.
- the "constant region” or “constant domain” refers to the carboxy-terminal portions of the light and heavy chains that are not directly involved in the binding of the antibody to the antigen, but exhibit various effector functions, such as interaction with Fc receptors. .
- the term refers to the portion of an immunoglobulin molecule that has a more conserved amino acid sequence compared to other portions of the immunoglobulin, the variable region containing the antigen binding site.
- the constant region may contain the CH1, CH2 and CH3 regions of the heavy chain and the CL region of the light chain.
- the “framework” or “FR” refers to the variable region residues flanking the CDR.
- FR residues are present in, for example, chimeric, humanized, human, domain antibodies, diabodies, linear antibodies, and bispecific antibodies.
- FR residues are variable domain residues other than hypervariable region residues or CDR residues.
- the mesothelin (MSLN) binding domain may include a light chain variable region (VL) of an antibody represented by SEQ ID NO: 8, or a light chain variable region of an antibody encoded by the nucleotide sequence represented by SEQ ID NO: 9. (VL) may be included.
- the mesothelin (MSLN) binding domain may include the heavy chain variable region (VH) of the antibody represented by SEQ ID NO: 10, or the heavy chain variable region of the antibody encoded by the nucleotide sequence represented by SEQ ID NO: 11 (VH) may be included.
- VH heavy chain variable region
- VH the heavy chain variable region of the antibody represented by SEQ ID NO: 10
- VH the heavy chain variable region of the antibody encoded by the nucleotide sequence represented by SEQ ID NO: 11
- the light chain variable region includes an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence shown in SEQ ID NO: 8. It can be done, and also includes those encoded by a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleotide sequence shown in SEQ ID NO: 9.
- the heavy chain variable region includes an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence shown in SEQ ID NO: 10. It can be done, and also includes those encoded by sequences that are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the base sequence shown in SEQ ID NO: 11.
- the scFv has at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 amino acid residues between its VL region and VH region. , 18, 19, 20, 25, 30, 35, 40, 45, 50 or more linkers.
- the linker sequence may include any naturally occurring amino acid.
- the linker sequence may include the amino acids glycine and serine.
- the linker sequence comprises a set of glycine and serine repeats, such as (Gly 4 Ser)n, where n may be a positive number of 1 or more, preferably 3 or 4.
- the linker may include the amino acid sequence represented by SEQ ID NO: 12, or may be a linker encoded by the nucleotide sequence represented by SEQ ID NO: 13.
- the mesothelin (MSLN) binding domain may include an scFv capable of specifically recognizing mesothelin, and the scFv is represented by the amino acid sequences of SEQ ID NOs: 2, 3, and 4, respectively.
- a light chain variable region (VL) comprising light chain CDR1, CDR2, and CDR3;
- a linker comprising the amino acid sequence shown in SEQ ID NO: 12 or encoded by the nucleotide sequence shown in SEQ ID NO: 13;
- a heavy chain variable region (VH) comprising heavy chain CDR1, CDR2, and CDR3 represented by the amino acid sequences of SEQ ID NOs: 5, 6, and 7, respectively, but is not limited thereto.
- the mesothelin (MSLN) binding domain may include an scFv capable of specifically recognizing mesothelin, and the scFv may include the amino acid sequence shown in SEQ ID NO: 8, or Variable light chain region (VL) of the antibody encoded by the nucleotide sequence shown in SEQ ID NO: 9; A linker comprising the amino acid sequence shown in SEQ ID NO: 12 or encoded by the nucleotide sequence shown in SEQ ID NO: 13; and a variable heavy chain region (VH) of an antibody comprising the amino acid sequence represented by SEQ ID NO: 10 or encoded by the nucleotide sequence represented by SEQ ID NO: 11; but is not limited thereto.
- the chimeric antigen receptor of the present invention can be designed with a signal peptide added to direct the translated chimeric protein to the membrane.
- the signal peptide may be included in the amino-terminus (N-ter) of the chimeric antigen receptor.
- this signal peptide can be selectively cleaved from the mesothelin binding domain (eg, scFv) while the chimeric antigen receptor is processed in the cell and localized to the cell membrane.
- the signal peptide generally ranges from 15 to 30 amino acids.
- Non-limiting examples of the signal peptide in the present invention include CD8 signal peptide (amino acids 21), CD33 signal peptide (amino acids 17), CD4 signal peptide (amino acids 25), and IL-2R (CD25) signal peptide (amino acids 21). dog), trypsinogen-2 signal peptide (15 amino acids), VEGFR1 signal peptide (26 amino acids), EGFR signal peptide (24 amino acids), GMCSFR signal peptide (22 amino acids), IgVL signal peptide, IgVK signal peptide Or there may be Ig VH signal peptide, etc.
- the signal peptide may be a CD8 signal peptide, and preferably may include an amino acid sequence represented by SEQ ID NO: 14, or a signal peptide encoded by the nucleotide sequence represented by SEQ ID NO: 15. It can be.
- the signal peptide may include an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence represented by SEQ ID NO: 14, , also includes those encoded by sequences that are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the base sequence shown in SEQ ID NO: 15.
- the chimeric antigen receptor of the present invention may further include an extracellular spacer, that is, a hinge.
- the "hinge” refers to a flexible polypeptide connector region (also referred to herein as a "hinge region”) that provides structural flexibility and spacing to the flanking polypeptide regions and is used in natural or synthetic polypeptides. It can be composed of:
- the chimeric antigen receptor of the present invention can connect the mesothelin binding domain to the transmembrane domain described below through a hinge.
- the hinge is sufficiently flexible to allow the antigen binding domain to be oriented in different directions to facilitate antigen binding.
- the hinge may be a hinge region derived from IgG, and preferably may include the amino acid sequence of a human IgG1, IgG2, IgG3, or IgG4 hinge region. Additionally, the hinge may contain one or more amino acid substitutions and/or insertions and/or deletions compared to the wild-type (naturally occurring) hinge region. For example, His229 of the human IgG1 hinge may contain a sequence substituted with Tyr.
- the hinge includes all or part of the CD8, CD28, 4-1BB, OX40, CD3 zeta ( ⁇ ) chain, T cell receptor ⁇ or ⁇ chain, CD28, CD3 ⁇ , CD45 commonly used in the art.
- CD8, 4-1BB, OX40, CD3 zeta ( ⁇ ) chain, T cell receptor ⁇ or ⁇ chain, CD28, CD3 ⁇ , CD45 commonly used in the art.
- CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, ICOS, CD154 their functional derivatives, or combinations thereof.
- CD4 CD5
- CD8 CD9 CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, ICOS
- the hinge may be a CD8-derived hinge region, and preferably may include an amino acid sequence represented by SEQ ID NO: 16, or a hinge encoded by the nucleotide sequence represented by SEQ ID NO: 17. You can.
- the hinge may include an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence represented by SEQ ID NO: 16, and the sequence It also includes those encoded by sequences that are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the base sequence indicated by number 17.
- the chimeric antigen receptor of the present invention may further include a transmembrane domain.
- the transmembrane domain includes one or more additional amino acids adjacent to the transmembrane region, for example, one or more amino acids associated with the extracellular region of the protein from which the transmembrane domain is derived (e.g., amino acid 1 of the extracellular region, 2, 3, 4, 5, 6, 7, 8, 9, 10 and up to 15 amino acids) and/or one or more additional amino acids associated with the intracellular region of the protein from which the transmembrane protein is derived (e.g. It may contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, up to 15 amino acids in the region.
- one or more amino acids associated with the extracellular region of the protein from which the transmembrane domain is derived e.g., amino acid 1 of the extracellular region, 2, 3, 4, 5, 6, 7, 8, 9, 10 and up to 15 amino acids
- additional amino acids associated with the intracellular region of the protein from which the transmembrane protein is derived e.g. It may contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, up to 15 amino acids in the region.
- the transmembrane domain is selected or has amino acid substitutions to prevent binding of this domain to the transmembrane domain of the same or another surface membrane protein, for example to minimize interaction with other members of the receptor complex. It can be transformed by .
- the transmembrane domain may be of natural origin or recombinant origin.
- the domain may be derived from any membrane-bound or transmembrane protein.
- the transmembrane domain can transmit a signal to the intracellular domain whenever the chimeric antigen receptor binds to the target antigen.
- the transmembrane domain includes, for example, T cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8 (e.g., CD8 alpha, CD8 beta), CD9, CD16, CD22, CD33, CD37, CD64. , CD80, CD86, CD134, CD137, and may include the transmembrane region of the alpha, beta or zeta chain of CD154, but are not limited thereto.
- the transmembrane domain is a co-stimulatory signaling domain, such as MHC class I molecule, TNF receptor protein, immunoglobulin-like protein, cytokine receptor, integrin, signaling lymphocyte activation molecule (SLAM protein) ), activated NK cell receptor, BTLA, Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7 -H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta , IL2R gamma, IL7R alpha, ITGA4, V
- the transmembrane domain when the transmembrane domain is a synthetic domain, it may include hydrophobic residues such as leucine and valine, or triplets consisting of phenylalanine, tryptophan and valine may be found at both ends of the synthetic transmembrane domain. .
- the transmembrane domain may be a CD8 transmembrane domain, and preferably includes the amino acid sequence represented by SEQ ID NO: 18, or may be encoded by the nucleotide sequence represented by SEQ ID NO: 19.
- the transmembrane domain may include an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence represented by SEQ ID NO: 18. It also includes those encoded by a base sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the base sequence shown in SEQ ID NO: 19.
- the chimeric antigen receptor of the present invention has a cytoplasmic domain and may further include an intracellular signaling domain.
- the “intracellular signaling domain” generally induces activation of the normal effector function of the cell into which the chimeric antigen receptor has been introduced.
- the “effector function” refers to a specialized function of a cell.
- the effector function of a T cell may be, for example, cytolytic activity or helper activity, including secretion of cytokines.
- the “intracellular signaling domain” refers to a portion of a protein that converts an effector function signal and instructs the cell to perform a specialized function. Typically the entire intracellular signaling domain can be used, but in many cases the entire domain is not required to be used.
- intracellular signaling domain is thus meant to contain any truncated region of the intracellular signaling domain sufficient to transduce an effector function signal.
- intracellular signaling domains in the present invention include cytoplasmic sequences of the T cell receptor (TCR) and co-receptors that act cooperatively to initiate signal transduction after binding to the antigen receptor, as well as any derivatives of these sequences. Or there may be variants, and any recombinant sequences with the same functional capacity, etc. It is known that signals generated through TCR fragments are insufficient to fully activate T cells, and secondary and/or costimulatory signals are also required.
- TCR T cell receptor
- the primary signaling domain controls the primary activation of the TCR complex in a stimulatory or inhibitory manner.
- the primary intracellular cleavage domain that acts in a stimulatory manner may be a specific signaling motif known as an immunoreceptor tyrosine-based activation motif or ITAM.
- ITAMs containing primary intracellular signaling domains specifically used in the present invention include TCR zeta, FcR gamma, FcR beta, CD3 zeta, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, CD278. (also known as “ICOS”), Fc.epsilon.RI, DAP10, DAP12, and ITAM of CD66d, but are not limited thereto.
- the primary signaling domain may include a modified ITAM domain, for example, a mutated ITAM domain whose activity is altered (e.g., increased or decreased) compared to the original ITAM domain.
- a modified ITAM domain for example, a mutated ITAM domain whose activity is altered (e.g., increased or decreased) compared to the original ITAM domain.
- the intracellular signaling domain may comprise a primary signaling domain, e.g., the CD3 zeta signaling domain itself, or may be combined with any other preferred intracellular signaling domain available in the present invention. You can.
- the intracellular signaling domain of a CAR may include one or more co-stimulatory signaling domains along with a primary signaling domain, such as a CD3 zeta chain region.
- the “co-stimulatory signaling domain” includes the intracellular domain of a co-stimulatory molecule and is a cell surface molecule other than an antigen receptor or its ligand required for an effective response of lymphocytes to an antigen.
- examples of such molecules in the present invention include MHC class I molecules, TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocyte activation molecules (SLAM proteins), activated NK cell receptors, BTLA, Toll ligands.
- Receptor OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, CDS, ICAM-1, ICOS ( CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA- 1, ITGB7,
- the intracellular signaling domain may be designed to include one or more, or two or more, for example, 2, 3, 4, 5 or more co-stimulatory signaling domains.
- neighboring molecules may be connected directly, but by linker molecules. They may also be placed spaced apart.
- the linker molecule may be a glycine residue or an alanine residue, but is not limited thereto.
- the intracellular signaling domain may be a CD3 zeta signaling domain, and preferably includes the amino acid sequence represented by SEQ ID NO: 20, or is encoded by the nucleotide sequence represented by SEQ ID NO: 21. You can.
- the intracellular signaling domain may further include 4-1BB as a co-stimulatory signaling domain.
- the 4-1BB preferably includes the amino acid sequence represented by SEQ ID NO: 22, or may be encoded by the nucleotide sequence represented by SEQ ID NO: 23.
- the intracellular signaling domain may include a CD3 zeta signaling domain as a primary signaling domain and 4-1BB as a co-stimulatory domain, preferably 4-1BB.
- the CD3 zeta signaling domain may include the amino acid sequence represented by SEQ ID NO: 20, or may be encoded by the nucleotide sequence represented by SEQ ID NO: 21, and the 4-1BB is the amino acid sequence represented by SEQ ID NO: 22. It may include or be encoded by the nucleotide sequence shown in SEQ ID NO: 23.
- the intracellular signaling domain may be linked directly to the C-terminus of the transmembrane domain, but alternatively may be linked to a short oligopeptide or polypeptide linker, e.g., 2-10 amino acids in length. Can be connected by a linker.
- the type of the linker is not limited, but a non-limiting example may be a glycine-serine doublet.
- the chimeric antigen receptor may include the amino acid sequence represented by SEQ ID NO: 24, or may be encoded by the nucleotide sequence represented by SEQ ID NO: 26, but is not limited thereto.
- the chimeric antigen receptor may include the amino acid sequence represented by SEQ ID NO: 25, or may be encoded by the nucleotide sequence represented by SEQ ID NO: 27, but is not limited thereto.
- the cells may further include cells genetically engineered to express a peptide or fragment thereof capable of inhibiting the transforming growth factor- ⁇ (TGF- ⁇ ) signaling pathway.
- TGF- ⁇ transforming growth factor- ⁇
- the present invention includes cells genetically engineered to express both the chimeric antigen receptor and the peptide or fragment thereof that inhibit the transforming growth factor beta pathway, as well as cells genetically engineered to express the chimeric antigen receptor. It is also included in the purpose of the present invention to simultaneously include two types of cells and cells genetically engineered to express a peptide or fragment thereof that inhibits the transforming growth factor beta pathway.
- the "transforming growth factor- ⁇ (TGF- ⁇ )” refers to a cytokine belonging to the TGF- ⁇ family.
- TGF- ⁇ expressed in mammals include TGF- ⁇ 1 and TGF- ⁇ . Three are known: - ⁇ 2 and TGF- ⁇ 3.
- Signal transduction by TGF- ⁇ plays a critical role in various biological processes and performs various functions such as cell growth inhibition, apoptosis, differentiation, and epithelial-mesenchymal transition (EMT).
- EMT epithelial-mesenchymal transition
- the TGF- ⁇ signaling system is tightly regulated and plays a critical role in development and organ formation as well as maintaining cellular homeostasis. Therefore, disruption of TGF- ⁇ signaling can cause life-threatening diseases such as cancer, fibrosis, and congenital malformations.
- the peptide may include the amino acid sequence represented by SEQ ID NO: 28, preferably consisting of the amino acid sequence represented by SEQ ID NO: 28.
- sequence encoding the peptide may include the nucleotide sequence represented by SEQ ID NO: 29, preferably consisting of the nucleotide sequence represented by SEQ ID NO: 29.
- the peptide may bind to the TGF- ⁇ receptor (TGFBR1 and/or TGFBR2) to inhibit TGF- ⁇ signaling.
- TGFBR1 and/or TGFBR2 TGF- ⁇ receptor
- the peptide competes with TGF- ⁇ and binds to the TGF- ⁇ receptor. It may be that TGF- ⁇ signaling is inhibited through a mechanism that prevents TGF- ⁇ cytokines from binding to the TGF- ⁇ receptor.
- the peptide may inhibit TGF- ⁇ signaling by suppressing the expression level of TGF- ⁇ in cells.
- the peptide may inhibit TGF- ⁇ signaling in cells through an auto-inhibition pathway. It may be suppressing TGF- ⁇ signaling through a mechanism that reduces the expression level or reduces the extracellular emissions of TGF- ⁇ .
- the cells may be immune effector cells.
- the “immune effector cell” may be a lymphoid cell that participates in an immune response, such as promoting an immune effector response.
- lymphocytes refers to cells that are commonly found in lymph and include natural killer cells (NK cells), T cells, and B cells. Those skilled in the art will understand that the immune cell types listed above can be further divided into subtypes.
- the lymphocytes may be or include Natural Killer Cells (NK cells), but are not limited thereto.
- NK cells Natural Killer Cells
- the "Natural Killer Cells (NK cells)” are defined as large granular lymphocytes (LGL), which constitute three types of cells differentiated from common lymphoid progenitor cells-producing B and T lymphocytes.
- NK cells are known to differentiate and mature in the bone marrow, lymph nodes, spleen, tonsils, and thymus and enter the circulation.
- the NK cells may include any type of NK cell without limitation, for example, cultured NK cells, such as primary NK cells, NK cells from a cultured NK cell line, or NK cells obtained from a mammal. It may be an NK cell, but is not limited thereto.
- NK cells When NK cells are obtained from a mammal, the NK cells can be obtained from a number of sources, including but not limited to blood, bone marrow, lymph nodes, thymus, or other tissues or body fluids. NK cells may be concentrated or purified. The NK cells may preferably be human NK cells (eg, isolated from humans). NK cell lines are available, for example, from ATCC (American Type Culture Collection) and include, for example, NK-92 cells (ATCC CRL-2407), NK92MI cells (ATCC CRL-2408) or derivatives thereof, etc. .
- ATCC American Type Culture Collection
- a polynucleotide (or gene construct) encoding the above-mentioned chimeric antigen receptor and a polynucleotide (or gene) encoding a peptide or fragment thereof capable of inhibiting the transforming growth factor beta signaling pathway are included in one vector. construct), or a vector containing a polynucleotide (or gene construct) encoding the chimeric antigen receptor, and a peptide or fragment thereof capable of inhibiting the transforming growth factor beta signaling pathway.
- Encoding may include both types of vectors containing polynucleotides (or gene constructs).
- the "vector” refers to a recombinant vector that can be transfected into a suitable host cell to express a protein of interest, and refers to a genetic construct containing essential regulatory elements operably linked to express the gene insert.
- operably linked means that the nucleic acid expression control sequence and the nucleic acid sequence encoding the protein of interest are functionally linked to perform a general function. Operational linkage with a recombinant vector can be prepared using genetic recombination techniques well known in the art, and site-specific DNA cutting and ligation can be easily performed using enzymes generally known in the art. there is.
- various types of vectors such as nanoparticles, plasmids, viruses, and cosmids can be used as recombinant expression vectors for inserting the foreign genes.
- the type of recombinant vector is not particularly limited as long as it functions to express the desired gene and produce the desired protein in various host cells of prokaryotic and eukaryotic cells, but specifically, it has a highly active promoter and strong expression ability while maintaining a natural state. Vectors that can produce large quantities of foreign proteins of a similar form can be used.
- a variety of gene delivery vehicles are known in the art and include both viral and non-viral (e.g., naked DNA, plasmid) vectors.
- Viral vectors suitable for gene transfer are known to those skilled in the art.
- Non-limiting examples of the viral vectors include retroviral vectors (derived from Moloney murine leukemia virus vector (MoMLV), MSCV, SFFV, MPSV, SNV, etc.), lentiviral vectors (e.g., HIV-1, HIV-2) , derived from SIV, BIV, FIV, etc.), adenovirus (Ad) vectors, including replication-competent, replication-deficient and anergic forms thereof, adeno-associated virus (AAV) vectors, simian virus 40 (SV-40) vectors , bovine papilloma virus vector, Epstein Barr virus vector, herpes virus vector, chicken pox virus vector, Harvey rat sarcoma virus vector, rat mammary tumor virus vector, Rous s
- Non-viral vectors for gene transfer include naked DNA, plasmids, transposons, and mRNA.
- Non-limiting examples include pKK plasmid (Clonetech), pUC plasmid, pET plasmid (Novagen, Inc., Madison, Wis.), pRSET or pREP plasmid (Invitrogen, San Diego, Calif.), pMAL plasmid (New England Biolabs, Beverly , Mass.).
- vectors in the present invention can be introduced into many suitable host cells using methods disclosed or cited herein or otherwise known to those skilled in the art.
- a suitable expression vector of the present invention may include a base sequence encoding a signal peptide for membrane targeting or secretion in addition to expression control elements such as a promoter, start codon, stop codon, polyadenylation signal, or enhancer.
- the initiation codon and stop codon are generally considered to be part of the nucleotide sequence encoding the immunogenic target protein and must be functional in the subject when the genetic construct is administered and must be in frame with the coding sequence.
- the "promoter”, as used herein, refers to any sequence that regulates the expression of a coding sequence, such as a gene. Promoters can be, for example, constitutive, inducible, repressible, or tissue-specific.
- a promoter is a control sequence, a region of polynucleotide sequence where the initiation and rate of transcription is controlled.
- Non-limiting examples of the promoters in the present invention include Rous sarcoma virus (RSV) LTR promoter (optionally with RSV enhancer), cytomegalovirus (CMV) promoter, SV40 promoter, dihydrofolate reductase Promoter, ⁇ -actin promoter, phosphoglycerol kinase (PGK) promoter, U6 promoter, EF1alpha short form (EFS) promoter, human polypeptide chain elongation factor (EF1a) promoter, P5 promoter, Ubc promoter, CAG promoter, TRE promoter , UAS promoter, Ac5 promoter, polyhedrin promoter, CaMKIIa promoter, Gal1 promoter, TEF1 promoter, GDS promoter, ADH1 promoter, CaMV35S promoter, ubiquitin (Ubi) promoter
- the promoter can be coupled to an enhancer to increase transcription efficiency.
- the enhancer may include, but are not limited to, the RSV enhancer, the CMV enhancer, or the ⁇ -fetoprotein MERII enhancer.
- the promoter may be the SSFV promoter, preferably the SSFV promoter represented by SEQ ID NO: 30, but is not limited thereto.
- the polynucleotide (or gene construct) encoding the chimeric antigen receptor may include the base sequence represented by SEQ ID NO: 26, but is not limited thereto.
- the polynucleotide encoding the chimeric antigen receptor may include the base sequence represented by SEQ ID NO: 27, but is not limited thereto.
- the vector of the present invention may further include a sequence encoding a signal peptide upstream of the polynucleotide encoding a peptide or fragment thereof capable of inhibiting the transforming growth factor beta (TGF- ⁇ ) signaling pathway.
- TGF- ⁇ transforming growth factor beta
- the signal peptide may be an IL-2 signal peptide, and preferably includes the amino acid sequence represented by SEQ ID NO: 33, or is encoded by the nucleotide sequence represented by SEQ ID NO: 34. However, it is not limited to this.
- the vector may include one or more additional polypeptides, for example, a polynucleotide encoding one or more markers and/or one or more effector molecules.
- the one or more markers may include a transduction marker, a surrogate marker, and/or a selection marker.
- the additional nucleic acid sequences introduced, encoding one or more additional polypeptides may be nucleic acid sequences that can improve the efficacy of the therapy, such as by promoting the viability and/or function of the transferred cells; Nucleic acid sequences that provide genetic markers for evaluation and/or selection of cells, such as to assess survival or localization in vivo; Lupton S. D. et al., Mol.
- the marker may be a transduction marker or a surrogate marker.
- the transduction marker or surrogate marker can be used to detect cells into which a polynucleotide (or gene construct) of the present invention, that is, a polynucleotide containing a sequence encoding the peptide of the present invention or a fragment thereof, has been introduced.
- the transduction marker may indicate or confirm transformation of the cell
- the surrogate marker may be a protein prepared to be co-expressed on the cell surface together with the peptide or fragment.
- the surrogate marker may be a surface protein modified to have little or no activity.
- the surrogate marker may be encoded on the same polynucleotide encoding the peptide or fragment.
- the nucleic acid sequence encoding the peptide or fragment thereof may optionally be operably linked to a nucleic acid encoding a self-cleaving peptide or a peptide that causes ribosome skipping, such as a 2A sequence.
- the exemplary surrogate marker is a truncated form of a cell surface polypeptide, e.g., a non-functional, full-length form of the cell surface polypeptide that cannot or will not transmit signals or signals that would normally be transmitted and/or will be internalized. It may contain truncated forms that cannot or are not internalized.
- Exemplary truncated cell surface polypeptides include truncated forms of growth factors or other receptors, such as truncated human epidermal growth factor receptor 2 (tHER2), truncated epidermal growth factor receptor (tEGFR), or It may include prostate-specific membrane antigen (PSMA) or a modified form thereof, such as truncated PSMA (tPSMA).
- tEGFR may contain an epitope recognized by the antibody cetuximab (Erbitux) or other therapeutic anti-EGFR antibody or binding molecule, which identifies cells engineered with the tEGFR construct and the encoded exogenous protein. or to select and/or remove or isolate cells expressing the encoded exogenous protein.
- cetuximab an epitope recognized by the antibody cetuximab (Erbitux) or other therapeutic anti-EGFR antibody or binding molecule, which identifies cells engineered with the tEGFR construct and the encoded exogenous protein. or to select and/or remove or isolate cells expressing the encoded exogenous protein.
- the marker e.g., a surrogate marker
- the marker includes all or part of CD34 (e.g., a truncated form), NGFR, CD19, or truncated CD19, e.g., truncated non-human CD19.
- the marker is a detectable protein, such as a fluorescent protein, such as green fluorescent protein (GFP), enhanced green fluorescent protein (EGFP), such as super-fold GFP. , sfGFP), red fluorescent protein (RFP), such as tdTomato, mCherry, mStrawberry, AsRed2, DsRed or DsRed2, cyan fluorescent protein (CFP), blue green fluorescent protein (BFP) ), enhanced blue fluorescent protein (EBFP) yellow fluorescent protein (YFP) and its variants, including species variants, monomer variants and codon-optimized, stabilized and/or enhanced variants of fluorescent proteins. It may be or contain a variant.
- a fluorescent protein such as green fluorescent protein (GFP), enhanced green fluorescent protein (EGFP), such as super-fold GFP.
- sfGFP red fluorescent protein
- RFP red fluorescent protein
- CFP blue green fluorescent protein
- BFP blue green fluorescent protein
- EBFP enhanced blue fluorescent protein
- YFP yellow fluorescent protein
- the marker is an enzyme such as luciferase, E. coli-derived lacZ gene, alkaline phosphatase, secreted embryonic alkaline phosphatase (SEAP), chloramphenicol acetyl transferase (CAT), and ⁇ -gal. It is or includes lactosidase or ⁇ -glucuronidase ( ⁇ -glucuronidase, GUS). Expression of the enzyme can be detected by addition of a substrate that can be detected upon expression and functional activity of the enzyme.
- the marker may be green fluorescent protein (GFP), and preferably, the marker includes the amino acid sequence represented by SEQ ID NO: 31, or is encoded by the nucleotide sequence represented by SEQ ID NO: 32. It may be possible, but it is not limited to this.
- GFP green fluorescent protein
- the marker may be a selection marker.
- the selection marker may be or include a polypeptide that confers resistance to an exogenous agent or drug.
- the selection marker may be an antibiotic resistance gene, non-limiting examples include a puromycin resistance gene, hygromycin resistance gene, blasticidin resistance gene, neomycin resistance gene, geneticin resistance gene, or zeocin. It may be or contain a resistance gene or a modified form thereof.
- the vector includes a polynucleotide (or gene construct) encoding the chimeric antigen receptor; A polynucleotide (or gene construct) encoding a peptide or fragment thereof capable of inhibiting the transforming growth factor beta signaling pathway; and a polynucleotide (or gene construct) encoding a marker, but is not limited thereto.
- the vector includes a polynucleotide (or gene construct) encoding the chimeric antigen receptor in one vector; A polynucleotide (or gene construct) encoding a peptide or fragment thereof capable of inhibiting the transforming growth factor beta signaling pathway; and a polynucleotide (or gene construct) encoding a marker, but is not limited thereto.
- the position order or combination order of each of these genes in the vector is not particularly limited.
- the vector is a vector containing a polynucleotide (or gene construct) encoding the chimeric antigen receptor; And a vector containing a polynucleotide (or gene construct) encoding a peptide or fragment thereof capable of inhibiting the transforming growth factor beta signaling pathway; but is not limited thereto.
- the vector is a vector containing a polynucleotide (or gene construct) encoding the chimeric antigen receptor; And a vector containing a polynucleotide (or gene construct) encoding a peptide or fragment thereof capable of inhibiting the transforming growth factor beta signaling pathway, wherein a marker is added to at least one of the two vectors.
- Encoding polynucleotides (or gene constructs) may be additionally included, but are not limited thereto.
- polynucleotide when two separate polynucleotides (or gene constructs) are included in one vector, for example, a polynucleotide (or gene construct) encoding the chimeric antigen receptor in one vector; A polynucleotide (or gene construct) encoding a peptide or fragment thereof capable of inhibiting the transforming growth factor beta signaling pathway; And when at least two of the polynucleotides (or gene constructs) encoding the marker are included simultaneously, they may be operably linked by one promoter, or may be operably linked by two or more promoters.
- a self-cleavable peptide is provided so that each of them can be individually delivered or introduced into the cell for intracellular expression. It may further include a polynucleotide encoding.
- the "self-cleavage peptide” refers to 10 to 50, 12 to 42, 14 to 34 peptides that can induce cleavage of proteins synthesized within cells. It refers to a peptide consisting of 16 to 26 or 18 to 22 amino acids.
- the self-cleaving peptide may be derived from the 2A region of the viral gene.
- the self-cleaving peptide may be derived from P2A, E2A, F2A or T2A.
- the self-cleaving peptide may be derived from P2A.
- a peptide that is cleaved by a degrading enzyme present in the cytoplasm can be used.
- the self-cleavable peptide may be P2A or a peptide derived therefrom, and preferably includes the amino acid sequence represented by SEQ ID NO: 35, or is cleaved by the nucleotide sequence represented by SEQ ID NO: 36. It may be encrypted.
- a cell therapeutic agent comprising the genetically engineered cells provided by the present invention as an active ingredient.
- the “cell therapy” refers to a treatment using autologous, allogenic, or xenogenic cells to restore tissue function, and is used to suppress cancer. If the immune effector cells, for example, genetically modified natural killer cells, are included as active ingredients, they can be used as a cell therapy for the treatment and prevention of cancer.
- the cell therapeutic agent may further include a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier may be, for example, saline solution, sterilized water, Ringer's solution, buffered saline solution, dextrose solution, maltodextrin solution, glycerol, ethanol, HSA (Human serum albumin), and a mixture of one or more of these ingredients.
- Other common additives such as antioxidants, buffers, and bacteriostatic agents can be added as needed.
- the cell therapeutic agent may be used as a suspending agent, solubilizing agent, stabilizer, isotonic agent, preservative, anti-adsorption agent, surfactant, diluent, excipient, pH adjuster, analgesic agent, buffer, sulfur-containing agent, etc. ⁇ ) Reducing agents, antioxidants, etc. can be added appropriately.
- the suspending agent include, but are not limited to, methylcellulose, polysorbate 80, hydroxyethylcellulose, gum arabic, traganmal, sodium carboxymethylcellulose, polyoxyethylene sorbitan monolaurate, etc. no.
- the solution auxiliary agent includes polyoxyethylene hydrogenated castor oil, polysorbate 80, nicotinic acid amide, polyoxyethylene sorbitan monolaurate, mecrogol, castor oil fatty acid ethyl ester, etc.
- Stabilizers include, but are not limited to, dextran 40, methylcellulose, gelatin, sodium sulfite, and sodium metasulfate.
- the isotonic agent includes, for example, D-mannitol, sorbitol, etc., but is not limited thereto.
- the preservative includes, for example, methyl paraoxybenzoate, ethyl paraoxybenzoate, sorbic acid, phenol, cresol, chlorocresol, etc., but is not limited thereto.
- the anti-adsorption agent includes, for example, human serum albumin, lecithin, dextran, ethylene oxide propylene oxide copolymer, hydroxypropyl cellulose, methyl cellulose, polyoxyethylene hydrogenated castor oil, polyethylene glycol, etc. , but is not limited to this.
- the sulfur-containing reducing agent includes, for example, N-acetylcysteine, N-acetylhomocysteine, thioctoic acid, thiodiglycol, thioethanolamine, thioglycerol, thiosorbitol, thioglycolic acid and its salts, sodium thiosulfate, Examples include those having a sulfuhydryl group such as glutathione and thioalkanoic acid having 1 to 7 carbon atoms, but are not limited thereto.
- the antioxidants include, for example, erythorbic acid, dibutylhydroxytoluene, butylhydroxyanisole, ⁇ -tocopherol, tocopherol acetate, L-ascorbic acid and its salts, L-ascorbic acid palmitate, Chelating agents such as L-ascorbate stearate, sodium bisulfite, sodium sulfite, triamyl gallate, propyl gallate or sodium ethylenediaminetetraacetate (EDTA), sodium pyrophosphate, and sodium metaphosphate may be included, but are limited thereto. It doesn't work.
- the cell therapeutic agent is used, for example, based on an adult patient weighing 70 kg, about 1,000 to 10,000 cells/time, 1,000 to 100,000 cells/time, 1,000 to 1,000,000 cells/time, 1,000 to 10,000,000. , 1,000 ⁇ 100,000,000 cells/time, 1,000 ⁇ 1,000,000,000 cells/time, 1,000 ⁇ 10,000,000,000 cells/circuit, can be administered in divided doses once or several times a day at regular time intervals, or can be administered multiple times at regular time intervals.
- the injectable product according to the present invention can be manufactured in the form of a filled injection by taking the amount commonly known in the art depending on the patient's constitution and type of defect.
- the present invention relates to a pharmaceutical composition for preventing, improving or treating cancer containing the genetically engineered cells provided by the present invention as an active ingredient.
- cancer refers to or refers to a physiological condition typically characterized by uncontrolled cell growth in mammals.
- the cancer subject to prevention, improvement, or treatment in the present invention may be a solid tumor consisting of a lump generated by abnormal cell growth in a solid organ, and preferably expresses mesothelin (MSLN).
- MSLN mesothelin
- Any cancer that has cancer can be included without limitation, and specific examples include stomach cancer, liver cancer, glioblastoma, ovarian cancer, colon cancer, head and neck cancer, bladder cancer, renal cell cancer, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, biliary tract cancer, It may be melanoma or lung cancer, but is not limited thereto.
- prevention refers to all actions that inhibit cancer or delay its progression by administering the composition of the present invention.
- treatment and “improvement” mean any action in which cancer symptoms are improved or beneficially changed by administration of the composition of the present invention.
- the pharmaceutical composition of the present invention may be formulated to include one or more pharmaceutically acceptable carriers in addition to the active ingredients described above.
- Pharmaceutically acceptable carriers may be saline solution, sterile water, Ringer's solution, buffered saline solution, dextrose solution, maltodextrin solution, glycerol, ethanol, liposome, and a mixture of one or more of these ingredients, and if necessary, antioxidants.
- other common additives such as buffer solutions and bacteriostatic agents can be added.
- diluents, dispersants, surfactants, binders, and lubricants can be additionally added to formulate injectable formulations such as aqueous solutions, suspensions, and emulsions, as well as pills, capsules, granules, or tablets, and can act specifically on target organs.
- Target organ-specific antibodies or other ligands can be used in combination with the carrier.
- it can be preferably formulated according to each disease or ingredient using an appropriate method in the art or a method disclosed in Remington's Pharmaceutical Science (recent edition), Mack Publishing Company, Easton PA). there is.
- the pharmaceutical composition of the present invention can be a solution, suspension, dispersion, emulsion, gel, injectable solution, or sustained-release preparation of the active compound, and is preferably an injection.
- the pH is adjusted using a buffer solution such as an aqueous acid solution or phosphate that can be used as an injection to ensure product stability according to the distribution of the injection prescription, making the injection very physically and chemically stable. It can be manufactured with
- the injection can be prepared by dissolving it in water for injection along with a stabilizer or solubilizing agent and then sterilizing it, especially by high-temperature reduced-pressure sterilization or aseptic filtration.
- the water for injection may be distilled water for injection or a buffer solution for injection, for example, a phosphate buffer solution with a pH in the range of 3.5 to 7.5 or a sodium dihydrogen phosphate (NaH2PO4)-citric acid buffer solution.
- the phosphate salt used may be in the form of a sodium salt or potassium salt, an anhydrous or hydrated form, and may be in the form of citric acid or an anhydrous or hydrated form.
- the stabilizer used in the present invention includes sodium pyrosulfite, sodium bisulfite (NaHSO 3 ), sodium metabisulfite (Na 2 S 2 O 3 ), or ethylenediaminetetraacetic acid
- Solubilizing agents include bases such as sodium hydroxide (NaOH), sodium bicarbonate (NaHCO 3 ), sodium carbonate (NaCO 3 ) or potassium hydroxide (KOH), or acids such as hydrochloric acid (HCl) or acetic acid (CH 3 COOH).
- the injectable agent according to the present invention can be formulated to be bioabsorbable, biodegradable, and biocompatible.
- bioabsorbable we mean that the injectable agent can disappear from the body upon initial application without decomposition or decomposition of the dispersed injectable agent.
- Biodegradability means that the injectable agent can be broken down or decomposed in the body by hydrolysis or enzymatic degradation.
- Biosynthesis means that all ingredients are non-toxic to the body.
- the injection according to the present invention can be prepared using conventional fillers, weighting agents, binders, wetting agents, diluents such as surfactants, or excipients.
- composition or active ingredient of the present invention may be administered by intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, intranasal, subcutaneous, intrathecal, inhalational, topical, rectal, oral, intraocular or intradermal route depending on the purpose. It can be administered in a conventional manner, and preferably intravenously.
- the composition or active ingredient of the present invention can be administered by injection or catheter.
- the dosage of the active ingredient is 1 x 10 1 to 1 x 10 50 cells/kg, preferably 1 x 10 transformed host cells contained in the pharmaceutical composition, based on an adult weighing 60 kg. So that it can be administered within the range of 1 to 1 x 10 30 pieces/kg, more preferably 1 x 10 5 to 1 x 10 20 pieces/kg, and most preferably 1 x 10 7 to 1 x 10 9 pieces/kg. It can be adjusted.
- the optimal dosage to be administered can be easily determined by a person skilled in the art, and can be determined based on the type of disease, the severity of the disease, the content of the active ingredient and other ingredients contained in the composition, the type of dosage form, and the patient's age, weight, and general health. It can be adjusted according to various factors, including condition, gender and diet, administration time, administration route and secretion rate of the composition, treatment period, and concurrently used drugs.
- the active ingredient may be contained in an amount of 0.001 to 50% by weight based on the total weight of the composition.
- the content is not limited to this.
- composition of the present invention may further include one or more anticancer agents.
- the anticancer agents include nitrogen mustard, imatinib, oxaliplatin, rituximab, erlotinib, neratinib, lapatinib, gefitinib, vandetanib, nirotinib, semasanib, bosutinib, axitinib, Cediranib, lestaurtinib, trastuzumab, gefitinib, bortezomib, sunitinib, carboplatin, bevacizumab, cisplatin, cetuximab, Viscum album, asparaginase, tretinoin, hydroxycarbamide , dasatinib, estramustine, gemtuzumab ozogamycin, ibritumab tusetan, heptaplatin, methylaminolevulinic acid, amsacrine, alemtuzumab, procarbazin
- tezolomide busulfan, ifosphamide, cyclophosphamide, melphalan, altretmin, dacarbazine, thiotepa, nimustine, chlorambucil, mitolactol, leucovorin, tretonin, exemestane. , aminoglutethimide, anagrelide, navelvin, fadrazole, taciphen, toremifene, testolactone, anastrozole, letrozole, borozole, bicalutamide, lomustine and carmustine.
- One or more types selected from the group may be used, but are not limited thereto.
- a method for preventing, improving, or treating cancer which includes administering the cell therapy or pharmaceutical composition provided by the present invention to a subject.
- the subject may include, without limitation, mammals, birds, reptiles, farmed fish, etc., including rats, livestock, humans, etc., that develop or are at risk of developing cancer due to a TGF- ⁇ -related disease.
- the composition can be administered singly or multiple times in a pharmaceutically effective amount.
- the composition can be formulated and administered in the form of a solution, powder, aerosol, injection, infusion solution (injection), capsule, pill, tablet, suppository, or patch.
- the pharmaceutical composition for preventing or treating cancer may be administered through any general route as long as it can reach the target tissue.
- the composition is not particularly limited thereto, but depending on the purpose, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, transdermal patch administration, oral administration, intranasal administration, intrapulmonary administration, and intrarectal administration It can be administered through routes such as: However, when administered orally, it can be administered in an unformulated form, and since the active ingredients of the pharmaceutical composition may be denatured or decomposed by stomach acid, the oral composition must be coated with the active agent or protected from decomposition in the stomach. It can also be administered orally in formulated form or in the form of an oral patch. Additionally, the composition can be administered by any device that allows the active substance to move to target cells.
- the genetically engineered immune effector cells can target only target tumor cells by a chimeric antigen receptor targeting mesothelin (MSLN) expressed in the cells,
- MSLN chimeric antigen receptor targeting mesothelin
- TGF- ⁇ transforming growth factor beta
- TGF- ⁇ transforming growth factor beta
- Figure 2 shows an NK cell line genetically engineered to express a chimeric antigen receptor according to the present invention and a peptide that inhibits the TGF- ⁇ signaling pathway in the HCC-1806 breast cancer cell line into which a luciferase reporter gene was introduced in Experimental Example 1 of the present invention. The results of comparing luciferase activity after processing are shown in a graph.
- Figure 3 shows the MD-AMB-231 breast cancer cell line into which the luciferase reporter gene was introduced in Experimental Example 1 of the present invention, which was genetically engineered to express a chimeric antigen receptor according to the present invention and a peptide that inhibits the TGF- ⁇ signaling pathway.
- the results of comparing luciferase activity after treating NK cell lines are shown graphically.
- Figure 4 shows an NK cell line genetically engineered to express a peptide that inhibits the chimeric antigen receptor and TGF- ⁇ signaling pathway according to the present invention in the NCI-N87 gastric cancer cell line into which a luciferase reporter gene was introduced in Experimental Example 1 of the present invention. The results of comparing luciferase activity after processing are shown in a graph.
- Figure 5 shows that in Experimental Example 1 of the present invention, the AGS gastric cancer cell line into which the luciferase reporter gene was introduced was treated with an NK cell line genetically engineered to express a peptide that inhibits the chimeric antigen receptor and the TGF- ⁇ signaling pathway according to the present invention. The results of comparing luciferase activity are shown in a graph.
- Figure 6 shows a NK cell line genetically engineered to express a peptide that inhibits the chimeric antigen receptor and TGF- ⁇ signaling pathway according to the present invention in the NCI-H292 lung cancer cell line into which a luciferase reporter gene was introduced in Experimental Example 1 of the present invention. The results of comparing luciferase activity after processing are shown in a graph.
- Figure 7 shows NK genetically engineered to express a chimeric antigen receptor according to the present invention and a peptide that inhibits the TGF- ⁇ signaling pathway in the SW-620 colon cancer cell line into which a luciferase reporter gene was introduced in Experimental Example 1 of the present invention.
- the results of comparing luciferase activity after treating cell lines are shown graphically.
- Figure 8 shows NK genetically engineered to express a chimeric antigen receptor according to the present invention and a peptide that inhibits the TGF- ⁇ signaling pathway in the SNU-1544 colon cancer cell line into which a luciferase reporter gene was introduced in Experimental Example 1 of the present invention. The results of comparing luciferase activity after treating cell lines are shown graphically.
- Figure 9 shows the SK-HEP-1 liver cancer cell line into which the luciferase reporter gene was introduced in Experimental Example 1 of the present invention, which was genetically engineered to express a peptide that inhibits the chimeric antigen receptor and TGF- ⁇ signaling pathway according to the present invention.
- the results of comparing luciferase activity after treating NK cell lines are shown graphically.
- Figure 10 shows a NK cell line genetically engineered to express a peptide that inhibits the chimeric antigen receptor and TGF- ⁇ signaling pathway according to the present invention in the HEP-G2 liver cancer cell line into which the luciferase reporter gene was introduced in Experimental Example 1 of the present invention. The results of comparing luciferase activity after processing are shown in a graph.
- Figure 11 shows an NK cell line genetically engineered to express a peptide that inhibits the chimeric antigen receptor and TGF- ⁇ signaling pathway according to the present invention in the AsPC-1 pancreatic cancer cell line into which the luciferase reporter gene was introduced in Experimental Example 1 of the present invention. The results of comparing luciferase activity after processing are shown in a graph.
- Figure 12 shows a NK cell line genetically engineered to express a chimeric antigen receptor according to the present invention and a peptide that inhibits the TGF- ⁇ signaling pathway in the Capan-2 pancreatic cancer cell line into which a luciferase reporter gene was introduced in Experimental Example 1 of the present invention. The results of comparing luciferase activity after processing are shown in a graph.
- Figure 13 shows the change in pSmad2/3 expression level in Aspc1, a pancreatic cancer cell line, according to treatment with the peptide of the present invention in Reference Example 1 of the present invention.
- Figure 14 is a diagram showing the change in pSmad2/3 expression level in Bxpc3, a pancreatic cancer cell line, according to treatment with the peptide of the present invention in Reference Example 1 of the present invention.
- Figure 15 is a diagram showing the change in pSmad2/3 expression level in Panc1, a pancreatic cancer cell line, according to treatment with the peptide of the present invention in Reference Example 1 of the present invention.
- a chimeric antigen receptor (CAR) targeting mesothelin MSLN
- cells genetically engineered to express a peptide or fragment thereof capable of inhibiting the transforming growth factor- ⁇ (TGF- ⁇ ) signaling pathway a chimeric antigen receptor (CAR) targeting mesothelin (MSLN)
- TGF- ⁇ transforming growth factor- ⁇
- the chimeric antigen receptor includes a mesothelin binding domain, and may further include one or more selected from the group consisting of a hinge domain, a signal peptide domain, a transmembrane domain, and one or more signaling domains. .
- the mesothelin (MSLN) binding domain may include an scFv capable of specifically recognizing mesothelin, and the scFv is represented by the amino acid sequences of SEQ ID NOs: 2, 3, and 4, respectively.
- a light chain variable region (VL) comprising light chain CDR1, CDR2, and CDR3;
- a linker comprising the amino acid sequence shown in SEQ ID NO: 12 or encoded by the nucleotide sequence shown in SEQ ID NO: 13;
- a heavy chain variable region (VH) comprising heavy chain CDR1, CDR2, and CDR3 represented by the amino acid sequences of SEQ ID NOs: 5, 6, and 7, respectively, but is not limited thereto.
- the mesothelin (MSLN) binding domain may include an scFv capable of specifically recognizing mesothelin, and the scFv may include the amino acid sequence shown in SEQ ID NO: 8, or Variable light chain region (VL) of the antibody encoded by the nucleotide sequence shown in SEQ ID NO: 9; A linker comprising the amino acid sequence shown in SEQ ID NO: 12 or encoded by the nucleotide sequence shown in SEQ ID NO: 13; and a variable heavy chain region (VH) of an antibody comprising the amino acid sequence represented by SEQ ID NO: 10 or encoded by the nucleotide sequence represented by SEQ ID NO: 11; but is not limited thereto.
- the chimeric antigen receptor of the present invention can be designed with a signal peptide added to direct the translated chimeric protein to the membrane.
- the signal peptide may be a CD8 signal peptide, and preferably may include an amino acid sequence represented by SEQ ID NO: 14, or a signal peptide encoded by the nucleotide sequence represented by SEQ ID NO: 15. It can be.
- the chimeric antigen receptor of the present invention may further include an extracellular spacer, that is, a hinge.
- the hinge may be a CD8-derived hinge region, and preferably may include an amino acid sequence represented by SEQ ID NO: 16, or a hinge encoded by the nucleotide sequence represented by SEQ ID NO: 17. You can.
- the chimeric antigen receptor of the present invention may further include a transmembrane domain.
- the transmembrane domain may be a CD8 transmembrane domain, and preferably includes the amino acid sequence represented by SEQ ID NO: 18, or may be encoded by the nucleotide sequence represented by SEQ ID NO: 19.
- the chimeric antigen receptor of the present invention has a cytoplasmic domain and may further include an intracellular signaling domain.
- the intracellular signaling domain may be a CD3 zeta signaling domain, and preferably includes the amino acid sequence represented by SEQ ID NO: 20, or is encoded by the nucleotide sequence represented by SEQ ID NO: 21. You can.
- the intracellular signaling domain may further include 4-1BB as a co-stimulatory signaling domain.
- the 4-1BB preferably includes the amino acid sequence represented by SEQ ID NO: 22, or may be encoded by the nucleotide sequence represented by SEQ ID NO: 23.
- the intracellular signaling domain may include a CD3 zeta signaling domain as a primary signaling domain and 4-1BB as a co-stimulatory domain, preferably 4-1BB.
- the CD3 zeta signaling domain may include the amino acid sequence represented by SEQ ID NO: 20, or may be encoded by the nucleotide sequence represented by SEQ ID NO: 21, and the 4-1BB is the amino acid sequence represented by SEQ ID NO: 22. It may include or be encoded by the nucleotide sequence shown in SEQ ID NO: 23.
- the cells may further include cells genetically engineered to express a peptide or fragment thereof capable of inhibiting the transforming growth factor- ⁇ (TGF- ⁇ ) signaling pathway.
- TGF- ⁇ transforming growth factor- ⁇
- the peptide may include the amino acid sequence represented by SEQ ID NO: 28, preferably consisting of the amino acid sequence represented by SEQ ID NO: 28.
- sequence encoding the peptide may include the nucleotide sequence represented by SEQ ID NO: 29, preferably consisting of the nucleotide sequence represented by SEQ ID NO: 29.
- the peptide may bind to the TGF- ⁇ receptor (TGFBR1 and/or TGFBR2) to inhibit TGF- ⁇ signaling.
- TGFBR1 and/or TGFBR2 TGF- ⁇ receptor
- the peptide competes with TGF- ⁇ and binds to the TGF- ⁇ receptor. It may be that TGF- ⁇ signaling is inhibited through a mechanism that prevents TGF- ⁇ cytokines from binding to the TGF- ⁇ receptor.
- the cells may be immune effector cells.
- the immune effector cells are lymphoid cells that participate in an immune response, such as promoting an immune effector response, and may be or include Natural Killer Cells (NK cells), but are not limited thereto.
- NK cells Natural Killer Cells
- a vector containing a gene encoding the peptide or its fragment can be transfected into the immune effector cell to introduce a foreign gene encoding the peptide or its fragment into the cell.
- a polynucleotide (or gene construct) encoding the above-mentioned chimeric antigen receptor and a polynucleotide (or gene) encoding a peptide or fragment thereof capable of inhibiting the transforming growth factor beta signaling pathway are included in one vector. construct), or a vector containing a polynucleotide (or gene construct) encoding the chimeric antigen receptor, and a peptide or fragment thereof capable of inhibiting the transforming growth factor beta signaling pathway.
- Encoding may include both types of vectors containing polynucleotides (or gene constructs).
- a cell therapeutic agent comprising the genetically engineered cells provided by the present invention as an active ingredient.
- the present invention relates to a pharmaceutical composition for preventing, improving or treating cancer containing the genetically engineered cells provided by the present invention as an active ingredient.
- a peptide (P6) consisting of the amino acid sequence shown in SEQ ID NO: 28 targeting the TGF- ⁇ receptor was designed and produced.
- pancreatic cancer cell lines Aspc1, Bxpc3, and Panc1 cell lines were seeded in a 6-well plate at a concentration of 1 (Control group: 15% ACN - candidate peptide solvent, DMSO - P144 peptide solvent, P144: TSLDASIWAMMQNA (SEQ ID NO: 37)) and the expression levels of pSmad2/3 and total Smad2/3 were analyzed by Western blotting method.
- Example 1 Construction of a vector containing a chimeric antigen receptor and a TGF- ⁇ signaling pathway inhibitory gene
- the chimeric antigen receptor expression cassette includes CD8 signal peptide, mesothelin binding domain (light chain variable region; linker; and heavy chain variable region), CD8 hinge, CD8 transmembrane domain, 4-1BB, and CD3 zeta signaling domain.
- the recombinant gene was placed under the control of the SFFV single promoter.
- the base sequence of the SFFV promoter used in the experiment and the base sequences of each other gene are shown in Table 1, and the amino acid sequences encoded by these base sequences are shown in Table 2 below.
- Natural killer cells were used as immune effector cells to be genetically manipulated to express the chimeric antigen receptor and TGF- ⁇ signaling pathway inhibitory peptide.
- the NK-92 cell line was purchased from ATCC.
- the 293T cell line which is the cell line to be used to transduce the lentivirus, was also purchased from ATCC.
- Both the NK-92 cell line and the lentivirus-transduced NK-92 cell line described below were treated with 100 ⁇ g/mL of streptomycin, 100 units/mL of penicillin, and 20% fetal bovine serum. serum; FBS), 10% MEM vitamin solution, 1 streptomycin), 100 units/mL of penicillin, and 10% fetal bovine serum (FBS). All cells were cultured at 37°C with 5% CO2 (95% CO2). Cultured in an environment maintained with air.
- lentivirus In order to obtain a lentivirus of 5 , 5.5 ⁇ g of the lentiviral transfer vector (UCI-VD9 or UCI-VD35) prepared in Example 1, 3.7 ⁇ g of the packaging vector (UCI-VD6), and 1.8 ⁇ g of the envelope vector (UCI-VD11). Transfection was performed with lipofectamine 3000 transfection reagent. After transfection, the lentivirus produced in 293T cells was ejected out of the cell and existed in the cell culture medium in the form of virus particles. Accordingly, 48 or 72 hours after transfection, only the cell culture fluid was removed from the culture plate and concentrated 100 times with lenti-X concentration reagent (concentrator) to obtain lentivirus particles in the form of a pellet. Afterwards, 1 To select cell lines in which transduction was successful, cells expressing GFP were selected using a cell sorter (SH800S).
- SH800S cell sorter
- Pancreatic cancer cell lines (AsPC-1, Capan-2), breast cancer cell lines (HCC-1806, MDA-MB-231), stomach cancer cell lines (NCI-N87, AGS), lung cancer cell lines (NCI-H292), colon cancer cell lines (SNU- 1544, SW-620) and liver cancer cell lines (SK-HEP-1, Hep-G2) were purchased from the Korean Cell Line Bank (KCLB), and cell lines into which a luciferase reporter gene was introduced were used.
- KCLB Korean Cell Line Bank
- AsPC-1_luc_puro, Capan-2_luc_puro, HCC-1806_luc_puro, MDA-MB-231_luc_puro, NCI-N87_luc_puro, AGS_luc_puro, NCI-H292_luc_puro, SNU-1544_luc_puro and SW-620_luc_puro cell lines were cultured using RPMI-1640 medium.
- EP- 1_luc_puro and Hep-G2_luc_puro were cultured using high-glucose Dulbecco's modified Eagle medium.
- All media used for culturing cancer cell lines into which a luciferase reporter gene was introduced contained 100 ⁇ g/mL of streptomycin, 100 units/mL of penicillin, and 10% fetal bovine serum (FBS). ) and 4 ⁇ g/mL of puromycin were included. All cells were cultured at 37°C in an environment where CO 2 was maintained at 5% (95% air).
- NK-92 cells MSLN CAR+p6 peptide
- liver cancer cells were treated with an NK cell line genetically engineered to express a chimeric antigen receptor according to the present invention and a peptide that inhibits the TGF- ⁇ signaling pathway, the untreated group or the mock vector It was confirmed that the number of luciferase-expressing liver cancer cells was significantly reduced compared to the case of treating NK cells transfected with .
- pancreatic cancer cells when pancreatic cancer cells are treated with NK cells transduced with a mock vector, the killing effect on gastric cancer cells is minimal compared to the untreated group, whereas the chimeric antigen receptor and TGF- according to the present invention
- NK cell lines genetically engineered to express a peptide that inhibits the ⁇ signaling pathway were treated, it was confirmed that the death rate of pancreatic cancer cells was very high.
- the NK cell line genetically engineered according to the present invention can target cancer cells expressing mesothelin due to the chimeric antigen receptor expressed in the cells, and can target cancer cells expressing mesothelin by the peptide additionally expressed in the cells. It can be seen that through inhibition of the TGF- ⁇ signaling pathway, the ability of cells to invade into microtumors is improved, and the killing effect on cancer cells is also significantly increased.
- the present invention relates to immune effector cells genetically engineered to increase the therapeutic effect of diseases such as cancer by immunotherapy, and cell therapy products using the same.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne des cellules ayant été génétiquement modifiées pour exprimer un peptide ou un fragment de celui-ci pouvant inhiber la voie de signalisation du facteur de croissance transformant-β (TGF-β), en conjonction avec un récepteur antigénique chimérique (CAR) ciblant la mésothéline (MSLN).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2022-0150906 | 2022-11-11 | ||
KR1020220150906A KR20240081499A (ko) | 2022-11-11 | 2022-11-11 | 유전자 조작된 세포 및 이의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024101962A1 true WO2024101962A1 (fr) | 2024-05-16 |
Family
ID=91033328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2023/018102 WO2024101962A1 (fr) | 2022-11-11 | 2023-11-10 | Cellules génétiquement modifiées et leur utilisation |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20240081499A (fr) |
WO (1) | WO2024101962A1 (fr) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180021137A (ko) * | 2015-06-25 | 2018-02-28 | 아이셀 진 테라퓨틱스 엘엘씨 | 키메라 항원 수용체 (car), 조성물 및 이의 사용 방법 |
KR20180055824A (ko) * | 2015-08-21 | 2018-05-25 | 카르스젠 테라퓨틱스 리미티드 | 항 메소텔린 완전 인간 항체 및 메소텔린을 타겟팅하는 면역효과 세포 |
KR20180118175A (ko) * | 2016-03-04 | 2018-10-30 | 노파르티스 아게 | 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도 |
KR20210108290A (ko) * | 2020-02-25 | 2021-09-02 | (주)녹십자셀 | 메소텔린 특이적인 키메라 항원 수용체 및 이의 용도 |
KR20220091406A (ko) * | 2020-12-23 | 2022-06-30 | 한국과학기술연구원 | TGF-β 신호전달을 억제할 수 있는 신규한 펩타이드 및 이의 용도 |
-
2022
- 2022-11-11 KR KR1020220150906A patent/KR20240081499A/ko unknown
-
2023
- 2023-11-10 WO PCT/KR2023/018102 patent/WO2024101962A1/fr unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180021137A (ko) * | 2015-06-25 | 2018-02-28 | 아이셀 진 테라퓨틱스 엘엘씨 | 키메라 항원 수용체 (car), 조성물 및 이의 사용 방법 |
KR20180055824A (ko) * | 2015-08-21 | 2018-05-25 | 카르스젠 테라퓨틱스 리미티드 | 항 메소텔린 완전 인간 항체 및 메소텔린을 타겟팅하는 면역효과 세포 |
KR20180118175A (ko) * | 2016-03-04 | 2018-10-30 | 노파르티스 아게 | 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도 |
KR20210108290A (ko) * | 2020-02-25 | 2021-09-02 | (주)녹십자셀 | 메소텔린 특이적인 키메라 항원 수용체 및 이의 용도 |
KR20220091406A (ko) * | 2020-12-23 | 2022-06-30 | 한국과학기술연구원 | TGF-β 신호전달을 억제할 수 있는 신규한 펩타이드 및 이의 용도 |
Also Published As
Publication number | Publication date |
---|---|
KR20240081499A (ko) | 2024-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2761377C2 (ru) | Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15 | |
KR102572091B1 (ko) | 항 gprc5d 항체, gprc5d 및 cd3에 결합하는 이중특이성 항원 결합 분자, 및 이들의 용도 | |
WO2019225777A1 (fr) | Anticorps anti-ror1 et son utilisation | |
WO2019098682A1 (fr) | Anticorps anti-her2 ou fragment de liaison à l'antigène de celui-ci, et récepteur antigénique chimérique le comprenant | |
KR102527160B1 (ko) | 예정 사멸 1(pd-1)에 대한 신규한 단일클론성 항체 | |
WO2019225787A1 (fr) | Anticorps anti-b7-h3 et son utilisation | |
WO2019112347A2 (fr) | Anticorps ou son fragment de liaison à l'antigène pour reconnaître spécifiquement une malignité de cellule b, récepteur d'antigène chimérique le comprenant, et son utilisation | |
WO2021210939A1 (fr) | Afficorps anti-her2 et récepteur antigénique chimérique commutable utilisant celui-ci en tant que molécule de commutation | |
WO2018222019A1 (fr) | Nouveaux anticorps anti-cd40 et leur utilisation | |
WO2021235696A1 (fr) | Anticorps spécifique de cd22 et son utilisation | |
WO2019203600A1 (fr) | Molécule de commutation et récepteur antigénique chimérique commutable | |
WO2020005003A1 (fr) | Anticorps monoclonal se liant de manière spécifique à lag-3 et son utilisation | |
KR102115236B1 (ko) | 췌장 또는 담관계암 치료를 위한 키메라 항원 수용체 | |
WO2019125070A1 (fr) | Anticorps ou fragment de liaison à l'antigène de celui-ci reconnaissant spécifiquement des tumeurs malignes de lymphocytes b, récepteur antigénique chimérique le comprenant, et utilisations associées | |
WO2021060914A1 (fr) | Récepteur antigénique chimérique anti-claudine-3 | |
WO2024049161A1 (fr) | Nouveau récepteur antigénique chimérique anti-pd-l1 et cellules immunitaires l'exprimant | |
WO2024101962A1 (fr) | Cellules génétiquement modifiées et leur utilisation | |
WO2024101942A1 (fr) | Cellules génétiquement modifiées et leur utilisation | |
WO2021235697A1 (fr) | Anticorps spécifique de cd22 et son utilisation | |
WO2022124866A1 (fr) | Anticorps anti-pd-1 et ses utilisations | |
WO2022124864A1 (fr) | Anticorps anti-tigit et son utilisation | |
WO2021182929A1 (fr) | Anticorps spécifique à bcma et récepteur antigénique chimérique | |
WO2021225399A1 (fr) | Récepteurs antigéniques chimériques pour le traitement du cancer | |
EP4288081A1 (fr) | Car à base de ligands naturels modifiés : évolution dirigée du récepteur du stress nkp30 | |
WO2022139537A2 (fr) | Polypeptide spécifique de la mucine 1 et utilisation associée |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23889218 Country of ref document: EP Kind code of ref document: A1 |